Replimune (REPL) Assets (2018 - 2026)
Replimune (REPL) posted Assets of $332.4 million for Q1 2026, little changed sequentially from $333.6 million in Q4 2025, and down 39.71% YoY from $551.3 million in Q1 2025.
Analysis
Replimune (REPL) Assets (2018 - 2026) Analysis & Trends
Replimune has reported Assets for 9 years, with the latest figure at $332.4 million in Q1 2026.
- Quarterly Assets fell 39.71% year-over-year to $332.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $332.4 million (down 39.71% YoY) and the FY2026 annual result came in at $332.4 million, down 39.71% from the prior year.
- Assets was little changed at $332.4 million in Q1 2026 per REPL's latest filing, from $333.6 million in the prior quarter.
- Over five years, Assets peaked at $678.6 million in Q4 2022 and troughed at $332.4 million in Q1 2026.
- A 5-year average of $504.8 million and a median of $498.2 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2023 and 2025: Assets surged 40.2% in 2023, then slumped 44.74% in 2025.
- Over 5 years, Assets stood at $678.6 million in 2022, then declined by 21.46% to $532.9 million in 2023, then advanced by 13.27% to $603.6 million in 2024, then slumped by 44.74% to $333.6 million in 2025, then declined by 0.36% to $332.4 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $332.4 million, $333.6 million, and $389.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Replimune | 1.45 Bn | 1.45 Bn | - | 252.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 252.45 Mn |
| Mar 31, 2026 | 332.39 Mn |
| Dec 31, 2025 | 333.59 Mn |
| Sep 30, 2025 | 389.45 Mn |
| Jun 30, 2025 | 469.51 Mn |
| Mar 31, 2025 | 551.33 Mn |
| Dec 31, 2024 | 603.63 Mn |
| Sep 30, 2024 | 498.20 Mn |
| Jun 30, 2024 | 534.97 Mn |
| Mar 31, 2024 | 487.72 Mn |
| Dec 31, 2023 | 532.93 Mn |
| Sep 30, 2023 | 562.40 Mn |
| Jun 30, 2023 | 603.89 Mn |
| Mar 31, 2023 | 646.59 Mn |
| Dec 31, 2022 | 678.55 Mn |
| Sep 30, 2022 | 436.10 Mn |
| Jun 30, 2022 | 459.43 Mn |
| Mar 31, 2022 | 461.19 Mn |
| Dec 31, 2021 | 485.28 Mn |
| Sep 30, 2021 | 503.46 Mn |